EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Recent Advances in the Applications of Small Molecules in the Treatment of Multiple Myeloma

Hanley N Abramson iD

International Journal of Molecular Sciences · 31.01.2023 · 24 (3) · 2645

DOI: 10.3390/ijms24032645 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 31.01.2023. Verfasst von Hanley N Abramson. Beteiligte Einrichtung: Department of Pharmaceutical Sciences, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, MI 48202, USA. Hauptthemen laut MEDLINE: Multiple Myeloma. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 200 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Therapy for multiple myeloma (MM), a hematologic neoplasm of plasma cells, has undergone remarkable changes over the past 25 years. Small molecules (molecular weight of less than one kDa), together with newer immunotherapies that include monoclonal antibodies, antibody-drug conjugates, and most recently, chimeric antigen receptor (CAR) T-cells, have combined to double the disease’s five-year survival rate to over 50% during the past few decades. Despite these advances, the disease is still considered incurable, and its treatment continues to pose substantial challenges, since therapeutic refractoriness and patient relapse are exceedingly common. This review focuses on the current pipeline, along with the contemporary roles and future prospects for small molecules in MM therapy. While small molecules offer prospective benefits in terms of oral bioavailability, cellular penetration, simplicity of preparation, and improved cost–benefit considerations, they also pose problems of toxicity due to off-target effects. Highlighted in the discussion are recent developments in the applications of alkylating agents, immunomodulators, proteasome inhibitors, apoptosis inducers, kinesin spindle protein inhibitors, blockers of nuclear transport, and drugs that affect various kinases involved in intracellular signaling pathways. Molecular and cellular targets are described for each class of agents in relation to their roles as drivers of MM.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple MyelomaHumansNeoplasm Recurrence, LocalProteasome InhibitorsImmunotherapyAntibodies, Monoclonal

Stichwörter der Autor:innen

cereblon E3 ligase modulatorsmelflufenmyelomaselinexorvenetoclax

Substanzen

Proteasome InhibitorsAntibodies, Monoclonal

Autor:innen und Institutionen

  • Department of Pharmaceutical Sciences, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, MI 48202, USA.

ORCID-Profile: Hanley N Abramson

Zitieren

APA

Abramson, H. N. (2023). Recent Advances in the Applications of Small Molecules in the Treatment of Multiple Myeloma. International Journal of Molecular Sciences, 24(3), 2645. https://doi.org/10.3390/ijms24032645

Vancouver

Abramson HN. Recent Advances in the Applications of Small Molecules in the Treatment of Multiple Myeloma. International Journal of Molecular Sciences. 2023;24(3):2645. doi:10.3390/ijms24032645

BibTeX
@article{Abramson2023,
  author = {Abramson, Hanley N},
  title = {Recent Advances in the Applications of Small Molecules in the Treatment of Multiple Myeloma},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  volume = {24},
  number = {3},
  pages = {2645},
  doi = {10.3390/ijms24032645}
}
Kostenlos starten →